Tag: Interventions Testing Program

In a new study published in Nature Aging, researchers have shown that aging is associated with a decreased expression of long transcripts over multiple tissues across several animal species [1]. Global changes It is well known that aging is accompanied by changes in the expression of many genes. Therefore, numerous studies have focused on identifying...

In a new study published in Aging Cell, researchers have tested several individual drugs and a combination of rapamycin plus acarbose as potential life extension agents in genetically heterogeneous mice [1]. Anti-aging agent testing Identification of successful anti-aging interventions is arguably one of the most challenging research problems to date. In addition to the complexity...

Scientists have found that canagliflozin, an anti-diabetes drug that is known to extend lifespan in mice, alleviates an array of age-related pathologies, albeit in males only [1]. Anti-diabetes and anti-aging Canagliflozin, a widely used anti-diabetes drug, belongs to the class of sodium glucose cotransporter 2 (SGLT2) inhibitors, which regulate glucose reabsorption by the kidneys. Recently,...

Richard A. Miller is a Professor of Pathology at the University of Michigan and the Director of Michigan's Paul F. Glenn Center for Biology of Aging Research. He is also a driving force behind the ITP, the Interventions Testing Program, created in the early 2000s to study the effect of various drugs on lifespan in...